Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biomed Pharmacother ; 83: 79-84, 2016 Oct.
Article in English | MEDLINE | ID: mdl-27470553

ABSTRACT

In this study, gambogic acid (GA) and retinoic acid chlorochalcone (RACC) co-loaded glycol chitosan nanoparticle was successfully developed and studied for its therapeutic efficacy against osteosarcoma cancer cells. The GA/RACC loaded glycol chitosan nanoparticles (RGNP) was nanosized and exhibited a controlled release of drug in either pH 7.4 and pH 5.0. Owing to the strong positive charge on the RGNP surface, efficiency cellular uptake was observed in cancer cells. Moreover, a synergistic combination of GA and RACC were effectively suppressed the tumor growth progression. The half maximal inhibitory concentration (IC50) values in MG63 cells were 0.89µg/ml and 0.35µg/ml for GA and RGNP after 24h. The results clearly suggest the synergist effect of GA and RACC in effectively inhibiting the cancer cell proliferation. The RGNP as expected induced a remarkably higher apoptosis of cancer cells with ∼28%. Overall, combination of GA and RACC encapsulated in a nanocarrier could be an effective strategy to treat osteosarcoma. Future studies will focus on the in vivo evaluation of GA/RACC-loaded polymeric nanoparticles.


Subject(s)
Antineoplastic Agents/therapeutic use , Cyclohexanones/therapeutic use , Nanomedicine/methods , Osteosarcoma/drug therapy , Tretinoin/analogs & derivatives , Xanthones/therapeutic use , Apoptosis/drug effects , Cell Line, Tumor , Cyclohexanones/chemistry , Cyclohexanones/pharmacology , Drug Liberation , Endocytosis/drug effects , Humans , Kinetics , Nanoparticles/chemistry , Nanoparticles/ultrastructure , Osteosarcoma/pathology , Treatment Outcome , Tretinoin/chemistry , Tretinoin/pharmacology , Tretinoin/therapeutic use , Xanthones/chemistry , Xanthones/pharmacology
2.
Int J Clin Exp Pathol ; 8(7): 8671-5, 2015.
Article in English | MEDLINE | ID: mdl-26339455

ABSTRACT

BACKGROUND: miR-153 has been found to be significantly decreased in non-small cell lung cancer (NSCLC) tissues; however, its clinical significance has not been investigated. METHODS: The expression patterns of miR-153 in 137 pairs of human lung cancer tissues and adjacent normal lung tissues were analyzed using qRT-PCR. The relationships between miR-153 expression and clinicopathological parameters were examined by chi-square test. Kaplan-Meier method and the log-rank test were used to determine the difference in overall survival (OS) rates between two groups. RESULTS: The expression of miR-153 was reduced significantly, compared with adjacent normal lung tissues (P<0.05). We observed that the expression level of miR-153 was positively correlated with the clinical stage (P=0.005), lymph node status (P=0.014), distant metastasis (P=0.004), and differentiated degree (P<0.001) in NSCLC patients. According to the Kaplan-Meier survival analysis, the patients with low miR-153 expression exhibited evidently poorer overall survival rates than those with high miR-153 expression (P=0.003). Multivariate analysis showed that the expression of miR-153 was an independent and significant factor associated with poor OS rates (P=0.002). CONCLUSION: Decreased expression of miR-153 might be a potential unfavorable prognostic factor for patients with NSCLC, and further studies would be needed to prove our findings.


Subject(s)
Biomarkers, Tumor/genetics , Carcinoma, Non-Small-Cell Lung/genetics , Lung Neoplasms/genetics , MicroRNAs/genetics , Carcinoma, Non-Small-Cell Lung/mortality , Carcinoma, Non-Small-Cell Lung/secondary , Carcinoma, Non-Small-Cell Lung/therapy , Cell Differentiation , Chi-Square Distribution , Down-Regulation , Female , Gene Expression Regulation, Neoplastic , Humans , Kaplan-Meier Estimate , Lung Neoplasms/mortality , Lung Neoplasms/pathology , Lung Neoplasms/therapy , Lymphatic Metastasis , Male , Middle Aged , Multivariate Analysis , Neoplasm Staging , Real-Time Polymerase Chain Reaction , Retrospective Studies , Risk Factors , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...